EraCal Therapeutics Ltd.
The biotech-company EraCal Therapeutics Ltd. is a spin-off from the University of Zurich and Harvard University. The company is privately held by a biotech-specialized investor base.
Founders
J. Jordi Ph.D.
Chief Executive Officer & Board Member
Josua Jordi is a biochemist ETH by training and completed a Ph.D. in physiology at the University of Zurich. He developed EraCal’s platform as a postdoctoral fellow at Harvard University.
S. Breitler Ph.D.
Chief Operational Officer
Simon Breitler holds a Ph.D. in synthetic organic chemistry from ETH Zurich which was complemented with a fellowship at Harvard University. He previously led a team in preclinical chemistry, manufacturing, and control (CMC) department at Roche.
Board of Directors
A. Kessler Ph.D.
Chairman
Ann Kessler held various senior research positions at Roche for over 26 years. She launched the obesity research program, led its clinical development, and brought orlistat (Alli, Xenical) to the market.
JM. Cosséry Ph.D.
Board Member
Jean-Michel Cosséry is a senior healthcare executive with global leadership experience in research, biotech, and commercial roles within Eli Lilly, GE Healthcare, Kymab Ltd, Immunocore Ltd. among others.
GK. Hamilton
Board Member
Gregory K. Hamilton is CEO of Epigenomics AG and has over 20 years of management experience in molecular diagnostics, manufacturing, and professional service industries.
B. Ernst Ph.D.
Board Member
Bettina Ernst is a biotech entrepreneur and investor. She serves the Swiss Biotech community in various roles thanks to her deep experience in medical research in the US and Europe.
Scientific Advisory Board
H. Böttcher Ph.D.
Henning Böttcher is the former head of medicinal chemistry at Merck KGaA.
Prof. F. Engert
Florian Engert is a neuroscience expert and tenured professor at Harvard University.
G. Meyer Ph.D.
Gerd Meyer is Head of Plexus Ventures CH, a leading global development & licensing firm.
Prof. T. A. Lutz
Thomas A. Lutz is an obesity and diabetes expert and tenured professor at the University of Zurich.
T. Weller Ph.D.
Thomas Weller is the former head of medicinal chemistry at Idorsia/Actelion.